Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819827 · ClinicalTrials.gov registry record
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 13
- Enrollment target
NCT05819827: Clinical Trial study, sponsored by Mayo Clinic.
NCT05819827 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05819827 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.
Primary Outcome
Evaluate the feasibility of patient recruitment by using descriptive statistics to determine number of patients approached and number of patients enrolled.
Interventions
- OTHER Blood and Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2024-05-21 |
Why NCT05819827 stopped before completion
NCT05819827 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood and Tissue is the first listed.
NCT05819827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05819827 about?
NCT05819827 is a clinical study titled "Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics". The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.
What is the current status of trial NCT05819827?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2023-04-19. Estimated completion is 2024-05-21.
What interventions are being tested in trial NCT05819827?
The interventions under investigation include: Blood and Tissue (OTHER).
Who is sponsoring clinical trial NCT05819827?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI